keyword
MENU ▼
Read by QxMD icon Read
search

hepatocellular carcinoma recent advances

keyword
https://www.readbyqxmd.com/read/28092171/a-pangenotypic-single-tablet-regimen-of-sofosbuvir-velpatasvir-for-the-treatment-of-chronic-hepatitis-c-infection
#1
Ilan S Weisberg, Ira M Jacobson
Hepatitis C virus (HCV) infects nearly 170 million people worldwide and is a leading cause of progressive liver damage, cirrhosis, and hepatocellular carcinoma. Curative therapies have historically relied on interferon-based treatments and were limited by significant toxicity and poor response rates, particularly among patients with prior treatment failure and advanced hepatic fibrosis. The recent advent of direct acting antiviral (DAA) agents which target key steps in the HCV viral life cycle has transformed the landscape of HCV treatment by offering highly effective and well tolerated interferon-free treatments...
January 16, 2017: Expert Opinion on Pharmacotherapy
https://www.readbyqxmd.com/read/28087399/advances-with-using-crispr-cas-mediated-gene-editing-to-treat-infections-with-hepatitis-b-virus-and-hepatitis-c-virus
#2
REVIEW
Buhle Moyo, Kristie Bloom, Tristan Scott, Abdullah Ely, Patrick Arbuthnot
Chronic infections with hepatitis B and hepatitis C viruses (HBV and HCV) account for the majority of cases of cirrhosis and hepatocellular carcinoma. Current therapies for the infections have limitations and improved efficacy is necessary to prevent complications in carriers of the viruses. In the case of HBV persistence, the replication intermediate comprising covalently closed circular DNA (cccDNA) is particularly problematic. Licensed therapies have little effect on cccDNA and HBV replication relapses following treatment withdrawal...
January 10, 2017: Virus Research
https://www.readbyqxmd.com/read/28052619/the-impact-of-direct-antiviral-agents-on-the-development-and-recurrence-of-hepatocellular-carcinoma
#3
REVIEW
María Reig, Loreto Boix, Jordi Bruix
Direct antiviral agents mark a major progress for the treatment of chronic hepatitis C virus infection. The rate of cure is higher than 90% in most populations and the safety profile is good. However, like any treatment, there are potential unexpected adverse events. Several reports have indicated that antiviral therapy may be associated with the reactivation of hepatitis B virus or the emergence of herpes virus in a time-related manner. Recently, several studies have described a potential unexpected incidence of hepatocellular carcinoma in treated patients, both in those without a prior history of cancer and those who have been successfully treated and were disease-free for different periods of time...
January 2017: Liver International: Official Journal of the International Association for the Study of the Liver
https://www.readbyqxmd.com/read/28045618/tumor-markers-for-early-diagnosis-for-brain-metastasis-of-hepatocellular-carcinoma-a-case-series-and-literature-review-for-effective-loco-regional-treatment
#4
Kenya Kamimura, Yuji Kobayashi, Yoshifumi Takahashi, Hiroyuki Abe, Daisuke Kumaki, Takeshi Yokoo, Hiroteru Kamimura, Norihiro Sakai, Akira Sakamaki, Satoshi Abe, Masaaki Takamura, Hirokazu Kawai, Satoshi Yamagiwa, Shuji Terai
Intrahepatic lesions of hepatocellular carcinoma (HCC) have been controlled by significant advances in treatment using loco-regional therapies, including, surgery, ablative therapy, catheter-based chemotherapy, and embolization. Consequently, the number of patients with extrahepatic metastatic lesions has increased. Their prognosis remains poor with approximately <1 year of survival from the time of diagnosis. A molecularly targeted drug, sorafenib, have been used to treat extrahepatic lesions and shown the prolonged survival time...
January 3, 2017: Cancer Biology & Therapy
https://www.readbyqxmd.com/read/28026002/microrna-33b-suppresses-the-proliferation-and-metastasis-of-hepatocellular-carcinoma-cells-through-the-inhibition-of-sal-like-protein-4-expression
#5
Qinggang Tian, Yao Xiao, Yanting Wu, Yun Liu, Zhiqing Song, Wenfeng Gao, Jing Zhang, Jingling Yang, Yuguo Zhang, Tuankui Guo, Furong Dai, Zhigang Sun
MicroRNAs (miRNAs or miRs) have been found to participate in the development and malignant progression of human cancers by negatively mediating the expression of their target genes. Recently, miR‑33b has been reported to be involved in multiple types of human cancer, including hepatocellular carcinoma (HCC). However, the underlying regulatory mechanisms of miR‑33b in HCC cell growth and metastasis remain largely unclear. In the present study, RT-qPCR revealed that miR‑33b was significantly downregulated in HCC tissues compared to their matched adjacent normal tissues...
November 2016: International Journal of Molecular Medicine
https://www.readbyqxmd.com/read/27995088/current-technical-issues-for-surgery-of-primary-liver-cancer
#6
REVIEW
Yoshikuni Kawaguchi, Goro Honda, Itaru Endo, Daniel Cherqui, Norihiro Kokudo
Primary liver cancer is the fifth most common cancer worldwide. Apart from liver transplantation, surgical resection has been accepted as the effective local treatment for hepatocellular carcinoma (HCC), one of the most common primary liver cancers. Recent technological innovations including navigation technology and intraoperative real-time fluorescence guidance have been utilized for liver resections in clinical practice. With respect to liver resection techniques, the laparoscopic approach has been increasingly gaining popularity as one of the minimally-invasive treatments of HCC...
November 2016: Liver Cancer
https://www.readbyqxmd.com/read/27995085/transarterial-therapies-for-hepatocellular-carcinoma
#7
REVIEW
Ezio Lanza, Matteo Donadon, Dario Poretti, Vittorio Pedicini, Marco Tramarin, Massimo Roncalli, Hyungjin Rhee, Young Nyun Park, Guido Torzilli
BACKGROUND: The treatment of hepatocellular carcinoma (HCC) is still a major health issue because of its increasing incidence and because of the complexity of its management. Transarterial embolization (TAE) and transarterial chemoembolization (TACE) are two widely used locoregional therapies in the treatment of HCC, especially for unresectable intermediate and advanced HCCs. SUMMARY: The modern use of TAE and TACE opens new scenarios for the treatment of unresectable HCC and has yielded interesting results...
November 2016: Liver Cancer
https://www.readbyqxmd.com/read/27957241/recent-advances-in-the-diagnosis-and-treatment-of-primary-biliary-cholangitis
#8
REVIEW
Ying-Qiu Huang
Primary biliary cholangitis (PBC), formerly referred to as primary biliary cirrhosis, is an infrequent progressive intrahepatic cholestatic autoimmune illness that can evolve into hepatic fibrosis, hepatic cirrhosis, hepatic failure, and, in some cases, hepatocellular carcinoma. The disease itself is characterized by T-lymphocyte-mediated chronic non-suppurative destructive cholangitis and elevated serum levels of extremely specific anti-mitochondrial autoantibodies (AMAs). In this article, we will not only review epidemiology, risk factors, natural history, predictive scores, radiologic approaches (e...
November 28, 2016: World Journal of Hepatology
https://www.readbyqxmd.com/read/27956256/circulating-micrornas-possible-role-as-non-invasive-diagnostic-biomarkers-in-liver-disease
#9
Kishor Pant, Senthil K Venugopal
Liver is the central organ for metabolism and the hepatocytes metabolize several drugs, hepatotoxins, alcohol, etc. Continuous exposure of the hepatocytes to these toxins result in various chronic diseases, such as alcoholic liver disease, non-alcoholic fatty liver disease, viral hepatitis and hepatocellular carcinoma. Although several diagnostic methods, such as serum markers, liver biopsy or imaging studies are currently available, most of these are either invasive or detect the disease at advanced stages...
December 9, 2016: Clinics and Research in Hepatology and Gastroenterology
https://www.readbyqxmd.com/read/27955729/malignant-tumors-of-the-liver-in-children
#10
Daniel C Aronson, Rebecka L Meyers
This article aims to give an overview of pediatric liver tumors; in particular of the two most frequently occurring groups of hepatoblastomas and hepatocellular carcinomas. Focus lays on achievements gained through worldwide collaboration. We present recent advances in insight, treatment results, and future questions to be asked. Increasing international collaboration between the four major Pediatric Liver Tumor Study Groups (SIOPEL/GPOH, COG, and JPLT) may serve as a paradigm to approach rare tumors. This international effort has been catalyzed by the Children's Hepatic tumor International Collaboration (CHIC) formation of a large collaborative database...
October 2016: Seminars in Pediatric Surgery
https://www.readbyqxmd.com/read/27935871/decreased-expression-of-protocadherin-20-is-associated-with-poor-prognosis-in-hepatocellular-carcinoma
#11
Yanqin Wu, Shuhui Zheng, Jiayan Yao, Minrui Li, Guang Yang, Ning Zhang, Shenghong Zhang, Bihui Zhong
Recently, protocadherin 20 has been reported as a tumor suppressor gene in hepatocellular carcinoma (HCC); however, the prognostic value of protocadherin 20 in HCC remains unclear. Hence, the purpose of this study was to investigate the clinical and prognostic values of protocadherin 20 in HCC patients. The expression of protocadherin 20 was assessed by quantitative real-time polymerase chain reaction, western blot, and immunohistochemistry. Kaplan-Meier curves were created to calculate the overall survival of the patients, and Cox regression models were used to identify the risk factors associated with prognosis...
December 7, 2016: Oncotarget
https://www.readbyqxmd.com/read/27920520/ligand-based-targeted-therapy-a-novel-strategy-for-hepatocellular-carcinoma
#12
REVIEW
Min Li, Weiyue Zhang, Birong Wang, Yang Gao, Zifang Song, Qi Chang Zheng
Hepatocellular carcinoma (HCC) is the most common primary liver cancer with high morbidity and mortality worldwide. Chemotherapy is recommended to patients with intermediate or advanced stage cancer. However, the conventional chemotherapy yields low desired response rates due to multidrug resistance, fast clearance rate, nonspecific delivery, severe side effects, low drug concentration in cancer cells, and so on. Nanoparticle-mediated targeted drug delivery system can surmount the aforementioned obstacles through enhanced permeability and retention effect and active targeting as a novel approach of therapeutics for HCC in recent years...
2016: International Journal of Nanomedicine
https://www.readbyqxmd.com/read/27904861/a-recent-advance-in-image-guided-locoregional-therapy-for-hepatocellular-carcinoma
#13
REVIEW
Yaoping Shi, Bo Zhai
BACKGROUND: Hepatocellular carcinoma (HCC) is the fifth most common cancer worldwide and the third most common cause of cancer-related deaths. Hepatic resection and liver transplantation are considered to be the preferred treatment for HCC. However, as novel therapeutic options such as image-guided locoregional therapies have emerged and been refined, the manner in which HCC is treated has changed dramatically compared with what it was considered just 2 decades earlier. SUMMARY: This study reviews the current results of various image-guided locoregional therapies for treating HCC, especially focusing on thermal ablative and transarterial techniques...
October 2016: Gastrointestinal Tumors
https://www.readbyqxmd.com/read/27899961/the-ras-raf-mek-erk-signaling-pathway-and-its-role-in-the-occurrence-and-development-of-hcc
#14
Lei Li, Guo-Dong Zhao, Zhe Shi, Li-Li Qi, Li-Yuan Zhou, Ze-Xian Fu
Hepatocellular carcinoma (HCC) is the fifth most common tumor worldwide and has a very poor prognosis. Its occurrence has been on the increase in recent years. Surgical resection and liver transplantation are the primary methods of treatment for HCC patients, but can only be applied to 15% of patients. The median survival time of unresectable or metastasizing HCC patients is only a few months. Existing systemic treatment methods are not effective for advanced HCC patients and a new method of treatment is needed for these patients...
November 2016: Oncology Letters
https://www.readbyqxmd.com/read/27895396/genetic-alterations-in-hepatocellular-carcinoma-an-update
#15
REVIEW
Zhao-Shan Niu, Xiao-Jun Niu, Wen-Hong Wang
Hepatocellular carcinoma (HCC) is one of the leading causes of cancer-related deaths worldwide. Although recent advances in therapeutic approaches for treating HCC have improved the prognoses of patients with HCC, this cancer is still associated with a poor survival rate mainly due to late diagnosis. Therefore, a diagnosis must be made sufficiently early to perform curative and effective treatments. There is a need for a deeper understanding of the molecular mechanisms underlying the initiation and progression of HCC because these mechanisms are critical for making early diagnoses and developing novel therapeutic strategies...
November 7, 2016: World Journal of Gastroenterology: WJG
https://www.readbyqxmd.com/read/27887628/implications-of-vessel-co-option-in-sorafenib-resistant-hepatocellular-carcinoma
#16
Elizabeth A Kuczynski, Robert S Kerbel
The reason why tumors generally have a modest or transient response to antiangiogenic therapy is not well understood. This poses a major challenge for sorafenib treatment of advanced hepatocellular carcinoma (HCC) where alternate therapies are lacking. We recently published a paper entitled "Co-option of liver vessels and not sprouting angiogenesis drives acquired sorafenib resistance in hepatocellular carcinoma" in the Journal of the National Cancer Institute, providing a potential explanation for this limited benefit...
November 25, 2016: Chinese Journal of Cancer
https://www.readbyqxmd.com/read/27882776/benefits-of-long-term-therapy-with-nucleos-t-ide-analogues-in-treatment-na%C3%A3-ve-patients-with-chronic-hepatitis-b
#17
Lai Wei, Jia-Horng Kao
OBJECTIVE: To assess the benefits of long-term nucleos(t)ide analogue (NA) therapy in reducing the severity and progression of liver disease in treatment-naïve patients with chronic hepatitis B (CHB). SCOPE: As complications of CHB, such as hepatic decompensation and hepatocellular carcinoma (HCC), take a long time to develop in patients with less advanced disease, the long-term benefits of NA therapy in such patients are more difficult to prove than short- or medium-term benefits...
December 21, 2016: Current Medical Research and Opinion
https://www.readbyqxmd.com/read/27878253/development-of-a-therapeutic-model-of-precancerous-liver-using-crocin-coated-magnetite-nanoparticles
#18
Rkia El-Kharrag, Amr Amin, Soleiman Hisaindee, Yaser Greish, Sherif M Karam
Despite considerable advances in understanding hepatocellular carcinoma, it is one of the common and deadliest cancers worldwide. Hence, increasing efforts are needed for early diagnosis and effective treatments. Saffron has been recently found to inhibit growth of liver cancer in rats. The aim of this study was to develop an effective method for treatment of liver cancer using magnetite nanoparticles (MNPs) coated with crocin, the main active component of saffron. MNPs were prepared and initially coated with dextran and a cross-linker to enhance conjugation of crocin using a modified coprecipitation method...
January 2017: International Journal of Oncology
https://www.readbyqxmd.com/read/27870678/interventional-oncology-in-hepatocellular-carcinoma-progress-through-innovation
#19
Lin Mu, Julius Chapiro, Jeremiah Stringam, Jean-François Geschwind
The clinical management of hepatocellular carcinoma has evolved greatly in the last decade mostly through recent technical innovations. In particular, the application of cutting-edge image guidance has led to minimally invasive solutions for complex clinical problems and rapid advances in the field of interventional oncology. Many image-guided therapies, such as transarterial chemoembolization and radiofrequency ablation, have meanwhile been fully integrated into interdisciplinary clinical practice, whereas others are currently being investigated...
November 2016: Cancer Journal
https://www.readbyqxmd.com/read/27855366/hox-antisense-lincrna-hoxa-as2-promotes-tumorigenesis-of-hepatocellular-carcinoma
#20
Fuqiang Wang, Huili Yang, Zhigang Deng, Yongjie Su, QinLiang Fang, Zhenyu Yin
BACKGROUND: Recent studies reveal that long non-coding RNAs (LncRNAs) play critical roles in the proliferation and migration of human cancer. Previous report has shown that LncRNA HOXA-AS2 was involved in carcinoma processes. However, the expression and biological function of HOXA-AS2 in hepatocellular carcinoma (HCC) are poorly understood. METHODS: Quantitative real-time PCR (qRT-PCR) was performed to detect the expression of HOXA-AS2 in HCC tissues and cell lines...
2016: Cellular Physiology and Biochemistry
keyword
keyword
69280
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"